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Abstract  
Anthracyclines such as doxorubicin and daunorubicin are anticancer drugs that act by damaging the DNA 
and used for treating a variety of cancers including adult acute myeloid leukemia.  To date, nearly 50 % of 
acute myeloid leukemia patients show resistance to anthracyclines although the cause is not known.  We 
first investigate if there is a relationship between the expression level of 23 DNA repair genes in three 
leukemic cell lines (KG-1, HL-60 and Mono-Mac1) and cellular responses to anthracyclines.  We 
observed that the DNA repair genes were all downregulated in these cell lines following exposure to 
doxorubicin.  Further analysis revealed that the general downregulation of the genes was linked to a 
substantial decrease in the recovery of total RNA raising the possibility that assessment of total RNA, and 
not specific gene or set of genes, can be used as a simple indicator of cellular responses to anthracyclines.  
Furthermore, examination of total protein extracts derived from these cell lines revealed for the first time 
that Ku70 is a key protein that remained stable, while the majority of proteins were loss, upon anthracycline 
treatment.  Importantly, Ku70 redistributes from the cytoplasm to the nucleoli in a time-dependent manner 
in response to anthracycline exposure.  We propose that Ku70 redistribution might play a vital role in 
predicting cellular response to anthracycline and promoting cell death. 
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Introduction  
The standard treatment for acute myeloid leukemia 
(AML) patients is a combination 
chemotherapy consisting of infusional cytarabine and 
an anthracycline such as daunorubicin [1]. The 
anthracycline drug family includes also doxorubicin, 
idarubicin and epirubicin and these chemotherapeutic 
agents act by intercalating with the DNA, producing a 
variety of DNA lesions that include DNA-adducts and 
DNA interstrand crosslinks [2, 3]. Anthracyclines can 
also generate reactive oxygen species (ROS) during 
metabolism leading to oxidative damage to the DNA 
such as modified bases and strand breaks [4-6]. In 
general, anthracyclines are highly genotoxic agents 
that potently inhibit DNA transactions such as DNA 
synthesis. It has been demonstrated that the efficiency 
in the repair of anthracycline-induced DNA lesions 
governs cellular responses to the drug. For example, 
cells deficient in XPA, a protein that is involved in the 
recognition of DNA damage in the nucleotide excision 
repair pathway or DNA polymerase eta (XPV) 
involved in bypassing thymine dimers, are highly 
sensitive to doxorubicin [7, 8]. In addition, a recent 
study showed that the expression level of the 
base-excision repair protein, the DNA glycosylase 
OGG1 involved in the repair of the oxidized DNA 
lesion 8-oxoG, is 7-fold reduced in AML patients [9]. 
These patients exhibit poor prognosis raising the 
possibility that OGG1 could play a role in enhancing 
the toxicity of the drug, perhaps by processing 8-oxoG 
to more toxic lesions [9]. Moreover, it has been shown 
that anthracyclines can inhibit the expression as well 
as the activity of poly (ADP-ribose) polymerase-1 
(PARP-1) [10]. Both OGG1 and PARP-1 belong to the 
base-excision repair pathway, which functions to 
repair oxidized DNA base lesions, 
apurinic/apyrimidinc (AP) sites, as well as DNA strand 
breaks with blocked 3'-termini [11]. Thus, it seems 
possible that the level of DNA repair genes could 
influence cellular responses to anthracyclines.  So far, 
no study has been undertaken to determine if there is a 
correlation between the expression levels of genes 
belonging to various DNA repair pathways and the 
sensitivity and resistance of AML cell lines to 
anthracyclines. 
 In this study, we set out to investigate the 
expression level of 23 genes that have been selected 
from the major DNA repair pathways including 
base-excision, nucleotide excision, mismatch and 
recombination. We examined the expression level of 
these genes in three leukemia cells lines using the 
Gene Expression Profiler. This state-of-art technology 
employs RT-PCR combined with capillary 
electrophoresis and can detect the expression level of 
at least 30 genes from a single sample 
(https://www.beckmancoulter.com/). In this report, we 
found no difference in the expression level of the DNA 
repair genes between three leukemic cell lines: HL60, 
Mono-Mac-1 and KG-1 under normal growth 
conditions. In contrast, exposure to the anthracycline 
doxorubicin caused a drastic reduction in the DNA 
repair genes in HL60 and Mono-Mac-1 cell lines, 
while 10-fold higher drug concentration was required 
to produce a similar effect in the KG-1 cell line, except 
for two genes, APE1 and PCNA, which remained 
partially expressed. Interestingly, anthracycline 
treatment triggered a substantial decrease in the 
recovery of total RNA from these cell lines, but which 
was dependent on the drug concentration. This 
observation raises the possibility that assessment of 
total RNA can be used as a simple indicator of cellular 
responses to anthracyclines. Herein, we also show for 
the first time that Ku70 is a key protein that remained 
stable following chronic exposure of the cells to 
anthracycline. Importantly, Ku70 redistributes from 
the cytoplasm to the nucleoli in a time-dependent 
manner in response to anthracycline exposure. We 
discuss the possible roles for the relocalization of 
Ku70 in leukemic cells following the drug treatment. 
Materials and methods 
Cell lines and materials 
KG1, HL60 and Mono-Mac1 are human leukemia cell 
lines, obtained from The Quebec Leukemia Cell Bank 
(QLCB), Montreal, Canada. PARP1 (F-2 ), Ku70 
(A-9), β- actin ( AC-15) and mouse IgG-FITC  
antibodies were purchased from Santa Cruz 
Biotechnology, Santa Cruz, CA, USA. The 
anthracyclines: Doxorubicin, daunorubicin, idarubicin 
and epirubicin were purchased from 
Maisonneuve-Rosement Hospital, Montreal, Canada. 
Cell culture  
Human leukemia cell lines, KG-1, HL60 and 
Mono-Mac1 were cultured in RPMI 1640 medium 
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supplemented with 20% of FBS, 100 U⁄ ml penicillin 
and 100 µg ⁄ ml streptomycin. All cells were cultured 
at 37°C in a humidified atmosphere with 5% CO2.  
MTT assay 
The leukemic cell lines were seeded in 96 well plate as 
4x104 cells per 200µl of medium per well with 
increasing concentration of each drug. After 24, 48 and 
72 hours of incubation, 10 µl of 5mg ⁄ mL of 
Methylthiazolyldiphenyl-tetrazolium bromide (MTT) 
(Sigma-Aldrich, Ltd, Ontario, Canada ) in PBS was 
added to each well and incubated for another 3 hours 
at 37°C. The reaction was stopped by adding DMSO 
(Sigma lifesciences, Canada) in each well to dissolve 
the MTT crystals. The absorbance of each sample was 
then determined at 540 nm following the 
manufactured instructions using ELx808 Absorbance 
Microplate Reader (Biotek, Winooski, USA). All 
experiments were performed in triplicate. 
RNA extraction for GeXP analysis 
mRNA extraction was performed with the RNeasy 
Mini kit (Qiagen Sciences, Maryland, USA), 
following user guide lines. The extraction was done 
after treatment with or without doxorubicin at different 
time point. Briefly, cells at 10x106 were treated with 
Doxorubicin (72 hours at 0.5 and 5 µM) for GeXP 
analysis. After treatment, the mRNA were extracted in 
triplicate and quantified for the analysis. 
Multiplex analysis by GeXP system 
Primer design of the set of 23 genes (see Table I and 
suppl. Table SI) was done using the eXpress Designer 
module of the express Profiler software (Beckman 
Coulter). 25 ng RNA were used in a 20 µL reaction 
volume for RT. Kanamycin RNA, an internal positive 
control was included. The RT reaction was performed 
as described before in [12] using the GenomeLab TM 
GeXP Start Kit (Beckman Coulter). Expression 
analysis was carried out with the GenomeLab TM 
GeXP system (Beckman-Coulter) following 
manufacturer’s instructions using the fragment 
analysis method. The data was normalized to 
Kanamycin before being expressed as a Mean 
Normalized Expression.  
Western Blot analysis 
Equal amounts of protein (50 µg) were separated by 
sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. After immunoblotting with 
anti-PARP1, anti-XRCC6 antibodies, nitrocellulose 
membranes (Biorad, Hercules, CA, USA) were 
reprobed with anti-β-actin, ensuring equal protein 
loading.  
Apoptosis assay   
Cells (~ 5 X 105) were pelleted (1000 rpm for 1 min) 
and washed with 1 ml of cold 1X PBS.  The cells 
were then incubated for 20 min in the dark with 5 μl of 
7-Amino-actinomycin D (7AAD), 1 μl  of Annexin V 
(PharMingen, US) and 10 μl of binding buffer (100 
mM Hepes pH 7.4, 140 mM NaCl, 25 mM CaCl2).  
Controls were incubated either with the binding buffer 
or with annexin V.  Another 400 μl of binding buffer 
was added to each of the samples before FACScan 
analysis (FACSCalibur, BD Dickinson).  
Coomassie staining and mass spectrometry 
Cells were treated with Daunorubicin (5µM) for 72 
hours and then proteins were extracted using RIPA 
buffer. The proteins were quantified and 50 µg were 
loaded per well in 10% SDS-PAGE gel. The gel was 
stained with 0.5% Coomassie Blue G-250 prepared in 
50% methanol/10% acetic acid for 10 min and 
destained with 40% HPLC grade methanol/10% acetic 
acid. After, the band of interest was cut and sends for 
Identification by Mass spectrometry to Taplin 
Biological Mass Spectrometry Facility, Harvard 
Medical School. 
RT-PCR analysis 
Cells were seeded at 10x106 over night before treatment with 
daunorubicin for 3, 6 and 72 hours at 5 µM. 1µg of RNA 
was used per reaction. cDNA synthesis  and PCR on Gene 
Amp PCR System 2700 (Applied Biosystems, Carlsbad, CA, 
USA) were performed with three independent RNA 
preparations. The primers for GAPDH were the same used 
for the GeXP analysis (see supp. Table S1).  The XRCC6 
and OCTN2 primers were designed by Primer 3 software. 
OCTN2 primers: left primer: 
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5’-GTGCTGCCACTGTTTGCTTA-3’and right primer 
5’-GGACTGCTGCTTCTTGGAAC-3’. XRCC6 primers: 
left primer 5’- AAAAG ACTGGGCTCCTTGGT-3’ and 
right primer 5’- AGCAGCTCCTGCTTCTTCAG-3’. 
 Immunofluorescence 
Cells growing on 6 well plates were treated with Daunorubicin 
(5µM) at different time (1, 6 and 24 hours) then washed 
with PBS cold twice and fixed with FCM Fixation Buffer 
(Santa Cruz  Biotechnology, Santa Cruz, CA, USA) at 
room temperature for 30 min. The cells were then 
permeabilized using FCM Permeabilization Buffer 1x 
(Santa Cruz, CA, USA) for 5 min. Following two washes 
with PBS, cells were stained with diluted mouse anti-Ku70 in 
FCM Wash Buffer (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) for 30 min on ice. After washes, the cells 
were then stained with FITC-conjugated goat anti- mouse 
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA). Cells were mounted with UltraCruz™ Mounting 
Medium (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) containing 1.5 μg/ml of 
4',6-diamidino-2-phenylindole (DAPI), which is used to 
counterstained DNA. Images were taken using the 
Microscope confocal LSM 510 META Zeiss with the 
objectif 100x / 1.4 Plan-Apochromat 1.4 oil. 
Statistical analysis 
For survival curves analysis at least three independent 
experiments were performed and the standard 
deviations were calculated. For GeXP analysis the 
percentage CV was calculated for each replicate. 
Only % CV ≤ 20% was taken for analysis.  
Results 
Leukemic cell lines display varying 
sensitivities to anthracyclines 
To have a better insight into the mechanism of 
resistance to anthracyclines, we chose three leukemia 
cell lines and examined the sensitivity towards this 
drug family. As shown in Figure 1, all three cell lines 
displayed sensitivity to the anthracyclines after 72 h of 
treatment with doxorubicin, daunorubicin, idarubicin 
or epirubicin using MTT assay.  However, the KG-1 
cell line showed resistance only at lower 
concentrations (< 0.1 µM) of doxorubicin, 
daunorubicin, or epirubicin, suggesting that leukemia 
cells may habour defects that cause differential 
responses to the drugs. We next checked whether the 
responses of the leukemia cells towards the 
anthracyclines would correlate with the cleavage of 
PARP, a physiological process indicative of cells 
undergoing apoptosis [13]. In all three sensitive cell 
lines, PARP was cleaved from the 113 to the 89 kDa 
fragment upon treatment with daunorubicin (Figure 2). 
The 89 kDa fragment corresponds to the C-terminal 
cleaved product of PARP-1(p89) under genotoxic 
stress[14]. Amongst these cells, KG-1 showed the 
earliest cleavage of PARP, which occurred at approx. 3 
h and completely cleaved by 48 h (Figure 2B), while 
for HL-60 and Mono-Mac1 cleavage seemed to occur 
after 3 h and completed by 6 and 12 h, respectively 
(Figure 2A and C). These data indicate that indeed 
KG-1 responds differently to the anthracyclines, and 
that all three cell lines appear to undergo cell death via 
apoptosis when exposed to anthracyclines, although 
this process may be delayed in the KG-1 cells.  
 
 
 
 
 
 
 
 
Figure 1 Sensitivities of the leukemia cell lines towards 
anthracyclines. Cell survival of the cell lines (KG-1, 
Mono-Mac1 and HL-60) was monitored using the MTT 
assay and the indicated concentrations of the drugs.  Each 
plot line shows an average of the results of three 
experiments and the error bars indicate the standard 
deviation.  
 
 
 
 
 
 
 
Figure 2 Kinetics of anthracycline-mediated PARP-1 
cleavage in the leukemia cell lines. The leukemia cell lines 
were treated with daunorubicin (DNR) for the indicated 
time and total protein extracts (50 μg per lane) were 
resolved by 10% SDS-PAGE followed by Western blot 
analysis to monitor for PARP-1 cleavage using anti-PARP-1 
monoclonal antibody and for normalization with antibodies 
against β-actin. The results are representative of two 
independent experiments. 
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The leukemia cell lines display similar 
expression pattern of DNA repair genes under 
normal conditions 
Because anthracyclines act by damaging the DNA, we 
checked for the expression level of genes involved in 
DNA repair in these leukemia cell lines. We selected 23 
genes to be analyzed in the three leukemic cell lines (see 
Table S1), and these genes belonged to the base-excision, 
nucleotide-excision, mismatch and recombination DNA 
repair pathways. To our knowledge, no studies 
investigated the expression level, in particular, of the 
base-excision repair (BER) genes in these cell lines. The 
expression pattern of the 23 genes in the three leukemia 
cell lines was assessed using a Gene eXpression Profiler 
(GeXP) where the externally added kanamycin gene, 
Kan(r), was used for normalization. The base line for 
normal expression was set at 1.0, above 2.5 for genes that 
were overexpressed and below 0.5 for genes that were 
significantly downregulated. In the case of the BER 
pathway, APE1 (encoding an AP endonuclease) and 
PCNA (encoding a factor involved in DNA synthesis) 
were the only genes upregulated in all three leukemia cell 
lines (Figure 3A). Two other genes, PARP-1 (Poly ADP 
ribose polymerase) and UNG1 (uracil DNA glycosylase) 
were significantly upregulated in HL-60 and KG-1 
(Figure 3A). In contrast, the AML prognostic marker 
OGG1 (encoding 8-oxoG DNA glycosylase) was 
downregulated in two of the cell lines (KG-1 and 
Mono-Mac1) (Figure 3A). NEIL2, another DNA 
glycoslyase, was downregulated only in Mono-Mac1 cell 
line (Figure 3A). Thus, under normal growth conditions 
there appears to be no unique pattern of expression of the 
BER genes that would distinguish one cell line from the 
next, for example, both HL60 and Mono-Mac1 exhibited 
nearly identical sensitivities to the anthracyclines, yet the 
expression of many BER genes (e.g., APE1, NEIL2, 
PARP1, TDG and UNG) were significantly lower in the 
Mono-Mac1 cells (Figure 3A).  When similar analysis 
was performed for genes belonging to the mismatch, 
nucleotide excision, and recombinational DNA repair 
pathways (Figure 3B), again we found no striking 
differences amount these cell lines (Figure 3B), raising 
the possibility that the expression levels of DNA repair 
genes under normal growth conditions cannot be used as 
an approach to account for subtle differences in cellular 
responses to anthracyclines.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Expression pattern of DNA repair genes in the 
leukemia cell lines untreated and treated with doxorubicin. 
Total RNA was extracted from the cells (10x106) treated 
without (A and B) and with the indicated concentrations (C 
to F) of doxorubicin for 72 hours. Total RNA (25 ng) from 
each sample was analyzed by GeXP. A, C and E, genes 
selected from the BER pathway. B, D and F genes selected 
from other DNA repair pathways. G, Total RNA was 
extracted from the control cell line HEK293T treated 
without and with doxorubicin (5 µM for 72 hours) and the 
expression levels of the indicated gene and analyzed by 
GeXP.  The data is the average of three independent 
experiments and each sample was analyzed in triplicate. 
G  
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Doxorubicin treatment downregulates the 
expression of the DNA repair genes 
We next examined if treatment with anthracyclines could 
alter the expression of the DNA repair genes thereby 
influencing the responses of leukemic cells to the drug. 
Upon treatment with doxorubicin (0.5 µM for 72 h), 
surprisingly all the BER genes as well as genes 
belonging to the other DNA repair pathways were 
completely downregulated in the HL-60 and Mono-Mac1 
(Figure 3C and D) as compared to the untreated cells 
(Figure 3A and B, respectively). In contrast, most of the 
genes examined were not altered in the KG-1 cell line 
upon treatment with 0.5 µM of the drug (Figure 3C and 
D vs. Figure 3A and B, respectively). These data are 
consistent with the KG-1 cell line showing more 
resistance to the drug at 0.5 µM (Figure 1A). However, at 
10-fold higher concentration of doxorubicin, all the genes 
were now completely downregulated in the KG-1 cells, 
except for APE1 and PCNA (Figure 3E and F vs. A and B, 
respectively). Since nearly all of the DNA repair genes 
tested were completely downregulated in the cell lines in 
response to doxorubicin, we suggest that the drug may 
have a general effect in downregulating gene expression. 
In fact, this phenomenon was also observed in the kidney 
carcinoma cell line HEK293T (Figure 3G), suggesting 
that the downregulation of the DNA repair genes was not 
specific to the leukemic cells. 
Anthracyclines diminish the level of total RNA 
in the sensitive leukemic cell lines 
We assume that if doxorubicin globally blocked gene 
expression, then the total RNA would be reduced in the 
cell lines upon drug treatment. As shown in Figure 4, 
when the same amount of cells were analyzed, the 
recovery of total RNA from HL60 and Mono-Mac1 was 
very low upon treatment with 0.5 µM of the drug for 72 h, 
as compared to the untreated control (Figure 4, lane 1 vs 
2 and 4 vs 5, respectively). In fact, the Mono-Mac1 cell 
line was exquisitely sensitive to the loss of total RNA as 
compared to HL-60 (Figure 4). In contrast, the KG-1 cell 
line showed no loss of total RNA following treatment 
with 0.5 µM of the drug, unless these cells were treated 
with 10-fold higher drug concentrations (5.0 µM) as 
compared to the untreated conditions (Figure 4, lanes 8 
and 9 vs. 7). Similar results were obtained if the cell lines 
were treated with another anthracycline such as 
daunorubicin (data not shown).  The observation that 
the recovery of total RNA correlates with the sensitivities 
of the leukemia cell lines towards anthracyclines raises 
the possibility that rapid analysis of total RNA could be 
an indicator of cellular responses to the drugs. 
 
 
 
 
 
 
 
Figure 4 Recovery levels of total RNA from the untreated 
and doxorubicin-treated leukemia cell lines. Total RNA was 
extracted from 10x106 cells that were either untreated or 
treated with the indicated concentrations of doxorubicin 
(DXR) and equal volume containing the recovered total 
RNA was loaded per well onto a 1% agarose gel. Lanes 1, 4, 
7 and 10 no treatment; lanes 2, 5, 8 and 11 cells were treated 
with 0.5 µM of DXR and lanes 3, 6, 9 and 12 cells were 
treated with 5 µM of DXR. 
The recovery of total proteins from leukemic 
cells correlates with RNA level following 
exposure to daunorubicin 
Since the recovery of total RNA was diminished in a 
dose-dependent manner following exposure to 
doxorubicin, we checked if this would cause a 
corresponding decrease in total protein.  Briefly, the 
leukemic cell lines were treated with or without the 
anthracycline for various times up to 72 h and total 
proteins were analyzed by standard SDS PAGE stained 
with Coomassie (Figure 5A). When total soluble extracts 
were analyzed, there was a general and considerable loss 
of total proteins following treatment of the three cell 
lines with any of the anthracyclines (Figure 5A, lanes 2, 
4 and 6 vs, 1, 3 and 5, respectively, shown only for 
daunorubicin). Thus, it would appear that the loss of total 
protein in these cells correlates with the observed 
decrease recovery of total RNA in response to 
anthracyline exposure. 
It is noteworthy that the loss of total proteins from the 
control cell line HEK293T was substantially less when 
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compared to the leukemia cells following the same 
treatment conditions (see Figure 5D), suggesting that the 
leukemia cell lines may exhibit a distinct response from 
HEK293T.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Ku70 is not inducible, but remains the major 
polypeptide detected in the leukemia cell lines following 
daunorubicin treatment. A, the leukemia cell lines were 
untreated and treated for 72 hours with 5 µM of 
daunorubicin (DNR) and total protein extracts analyzed on 
SDS-PAGE stained with Coomassie.  B, Western blot 
showing the presence of Ku70 in the KG-1 cell line after 72 
hours treatment with DNR. The cell line was treated as 
above for various times and total cell extract analyzed by 
Western probed with anti-Ku70 and anti-β-actin, the control 
protein. C, RT-PCR showing that Ku70 expression is not 
induced by DNR. C, Cells were treated for various time (0, 
3, 6 and 72 hours) with 5 µM of DNR and total RNA 
isolated for RT-PCR analysis. OCTN2 and GAPDH were 
used as controls.  D and E, The control cell line HEK293T 
was treated with DNR and total protein analyzed by 
SDS-PAGE stained with Coomassie and by Western blot as 
in panels A and B, respectively. 
Ku70, a major protein that remains stable in 
the three cell lines in response to daunorubicin 
From the above data, we observed that not all the 
proteins completely disappeared following drug 
treatment of the three cell lines. A prominent polypeptide 
of nearly 70 kDa in size remained stable throughout the 
treatment and reproducibility seen in HL-60, KG-1 and 
Mono-Mac1 cells (Figure 5A, lanes 2, 4 and 6). We 
excised this polypeptide and determined its sequence by 
mass spectrometry (see Materials and Methods). The 
major protein identified (15 peptides 30.5 % coverage of 
the entire protein) corresponded to sequences that 
matched XRCC6/Ku70 (SWISS-PROT: P12956). Ku70 
is a 70 kDa protein that plays multiple roles including the 
ability to repair DNA double strand breaks and prevent 
apoptosis [15, 16]. Western blot analysis revealed that 
indeed Ku70 remained stable following exposure to 
daunorubicin over 72 h, while the control protein β-actin 
was completely loss after 48 h (Figure 5B). There was no 
significant change in Ku70 protein level during the 72 h 
duration of daunorubicin exposure (Figure 5B). 
Moreover, we observed no induction of Ku70 gene 
expression following daunorubicin exposure, while a 
control gene OCTN2 encoding an organic cation 
transporter was downregulated (Figure 5C). These data 
suggest that the stability of Ku70 is not a result of 
enhanced gene expression.  In support of this, Ku70 
protein level was also not inducible in the HEK293T 
following exposure to daunorubicin (Figure 5E).   
Ku70 relocalizes from the cytoplasm to the 
nucleoli upon anthracycline exposure 
Besides Ku70 role in non-homologous end joining of 
DNA double strand breaks, it is also involved in several 
other biological processes [17, 18]. Ku70 has been 
reported to form a complex with the pro-apoptotic 
protein BAX in the cytoplasm and prevent cell death. We 
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reason that daunorubicin treatment may induce 
disassociation of the Ku70-BAX complex and promote 
Ku70 redistribution. Under normal condition, Ku70 was 
found to be distributed in the cytoplasm and the nucleus 
in the leukemic cell lines (Figure 6A, showing data for 
KG-1 cells).  The localization of Ku70 in the nucleus 
was not surprising due to its involvement in DNA repair. 
Following treatment of the cells with daunorubicin for 1 
hr, there was no change in the cellular distribution of 
Ku70. However, after 6 h treatment there was an increase 
in Ku70 associated foci in the nucleus, and which 
appeared to coincide with the kinetics of PARP cleavage 
(Figure 6). Interestingly, after 24 h treatment most of the 
Ku70 protein was localized to the nucleus and seemed to 
concentrate in the nucleoli (Figure 6B). After 24 h of 
drug treatment, the nuclei of these cells became rounded, 
a morphological shape that is indicative of cells 
undergoing death.  In fact, nearly 45 and 95 % of these 
cells were stained positive with annexin V after 24 and 
72 h, respectively, following exposure to daunorubicin 
(Figure 7), consistent with the cells undergoing cell death.  
Similarly, the control cells HEK293T were subjected to 
cell death upon treatment with daunorubicin (Figure 7). 
We interpreted these data to suggest that the movement 
of Ku70 from the cytoplasm to the nucleus may serve to 
set BAX free, allowing it to trigger apoptosis. 
 
 
 
 
 
 
 
Figure 6 Relocalization of Ku70 in the KG-1 cell line after 
DNR exposure. KG-1 cells were cultured at 1x106 in RPMI 
media without (A) and with 5 μM of DNR (B). Samples 
were taken at different times (1, 6 and 24 hours) and 
processed for immunofluorescence analysis using confocal 
microscopy. Ku70 cellular distribution was monitored by 
the fluorophore fluorescein isothiocyanate (FITC). 
Excitation lines, DNR (543 nm, HeNe laser); DAPI (405 nm, 
diode laser); and FITC (488 nm, Argon laser). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 DNR treatment triggers apoptosis in the leukemia 
and HEK293T cells. Cells were treated with DNR for the 
indicated time followed by FACS analysis to determine the 
fraction of cells staining positively with annexin V.  The 
data is an average from three experiments and the error bars 
indicate the standard deviation.  
Discussion 
The goal of our study was to investigate whether the 
expression levels of genes from various DNA repair 
pathways correlate with the cellular responses of 
leukemia cells towards anthracyclines. We focused 
specifically on anthracyclines as these are key anticancer 
agents used for treating AML, and which act by 
intercalating with the DNA to block several DNA 
transactions [2]. The prediction is that upregulation of 
DNA repair genes could be linked to AML patients who 
are resistant to induction-therapy with anthracycline. 
Herein, we found no convincing evidence, under normal 
growth conditions, that DNA repair genes are 
differentially expressed in the three cell lines, HL-60, 
KG-1 and Mono-Mac1. Moreover, we observed that in 
response to anthracyclines all of the tested DNA repair 
genes, except for APE1 and PCNA, were sharply 
downregulated even in the cell line KG-1 that showed 
resistance at lower drug concentrations, but required a 
higher dose to observe the phenomenon. The finding that 
nearly all of the DNA repair genes displayed a pattern of 
downregulation, and none showing upregulation, in the 
leukemia cells strongly suggests that resistance towards 
anthracyclines is unlikely to be associated with the 
expression levels of these genes. However, we have not 
investigated further whether either APE1 or PCNA or 
both of these genes would contribute directly to cause the 
resistance of KG-1 cells to low doses of anthracyclines. It 
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is noteworthy that PCNA encodes a clamp protein 
essential for DNA synthesis and which plays a central 
role in multiple DNA repair pathways [19, 20]. In fact, 
PCNA has been shown to interact with a number of DNA 
repair proteins such as KU70, MSH3, MSH6, MUTHY, 
FEN1, XRCC1 as well as others [21-26], strongly 
suggesting that PCNA could be a key factor governing 
resistance to anthracyclines. Nonetheless, we cannot 
exclude alternative possibilities that could explain the 
persistent presence of APE1 and PCNA in the resistant 
KG-1 cell line. For example, the transcripts of both genes 
could be more stable or induced in response to 
anthracyclines in this cell line and may have no direct 
consequences on drug resistance. 
 Because anthracyclines are powerful block to many 
DNA transactions including transcription [27] and that 
many of the genes examined above were all severely 
downregulated, we reasoned that the recovery of total 
RNA would likely be affected. Indeed we observed that 
the recovery of total RNA was greatly reduced when the 
more sensitive cell lines such as HL-60 and Mono-Mac1 
were treated with low doses of anthracyclines, but not 
from the resistant cell line KG-1. As such, it seems that 
the recovery of total RNA might be a better global and 
facile marker to monitor the responses of leukemic cells 
towards anthracyclines as opposed to examining the 
expression pattern of a subset of genes, particularly those 
involved in DNA repair. We propose that a simple 
protocol involving treatment of cultured patients’ blast 
cells with anthracyclines followed by analysis of RNA 
quality by a bioanalyzer would be an ideal approach to 
rapidly assess the drug responsiveness of the patients’ 
cells. This approach should represent a major advantage 
in terms of the rapidity in determining in advance 
whether a given patient would respond to drug treatment 
as opposed to starting the induction-therapy (lasting 7 
days) and waiting another 21 days to monitor the 
response. Establishing this in vitro approach has the 
benefit of providing the clinician with a direct tool to 
evaluate the outcome of patients’ responses and whether 
alternative regimen would be required. 
A novel observation emanating from our studies is the 
identification of Ku70 as a predominant protein that 
remained stable in drug sensitive leukemic cells, while 
the level of the majority of proteins were vanishingly low 
following exposure to anthracyclines. Of note, Ku70 
cellular distribution gradually shifted from the cytoplasm 
to the nucleoli and the earliest time of distribution 
coincides with PARP cleavage. Ku70 is the p70 subunit 
protein of the Ku70/80 complex which is involved in the 
non-homologous end joining DNA repair pathway that 
functions in the repair of DNA double-strand breaks[18]. 
It has been shown to have multiple cellular location 
including nuclear [28-33], plasma membrane [34], 
cytoplasmic [32], and both nuclear and cytoplasmic [35, 
36], indicative of roles other than that in DNA repair. In 
the cytosol, Ku70 has been shown to form a complex 
with CLU (clusterin) and the proapoptotic 
Bcl-2-associated X protein (BAX) [37]. This complex of 
Ku70-CLU-BAX has been shown to have increase levels 
in the cytosol of highly aggressive human colon cancers 
that resist cell death [38, 39]. It is believed that Ku70 
sequesters BAX preventing it from translocating to the 
mitochondria where it promotes the release of 
cytochrome C leading to the activation of caspases [40]. 
We reason that in response to anthracyclines, Ku70 may 
be modified and disassociate from BAX setting this latter 
protein free to induce apoptosis. We further suggest that 
the displaced Ku70 translocates to the nucleolus and may 
perform a role in this organelle. The nucleolus contains 
several key factors that function in sensing and repairing 
damage DNA and these include ATM, ATR, BLM, 
MRE11, PARP1, TOPBP1, WRN, XRCC1 and Ku70/80 
proteins [41]. Whether Ku70 relocalization is required to 
participate in the surveillance and repair of rDNA or 
suppress expression of this region in order to limit 
ribosomal biogenesis and trigger cell death will require 
additional experimentation. 
In summary, we have provided for the first time 
compelling evidence that shows a novel localization of 
Ku70 in the nucleoli of leukemic cells upon 
anthracycline treatment. We speculate that the 
relocalization of Ku70 to the nucleoli is unlikely to 
function in DNA repair, but participate in a process of 
cell death since these cells are undergoing apoptosis as 
determined by PARP cleavage. An interesting avenue to 
pursue is the mechanism that causes Ku70 to redistribute 
in response to anthracycline exposure in leukemic cells. 
Appendix A. Supplementary data 
Supplementary data associated with this article can be 
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found, in the online version, at 66-139-1-SP.xls  
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